65,437 trials
Neoplasm Metastases
Primary: Number of Subjects With Greater Than Grade 3 or 4 Toxicity — 1 participants
Influenza
Primary: Evaluation of Immunogenicity Measured by Seroconversion Rates of PanBlok With and Without Adjuvant Compared to Placebo in Healthy Adults 18-49 Years of Age. — 0; 32; 15…
Type 2 Diabetes Mellitus
Primary: Change in HbA1c From Baseline to Week 26 — -1.53; -1.48; -1.63; -1.15 percentage of total hemoglobin — p=0.620
Type II Diabetes
Primary: Systolic Blood Pressure, Change From Baseline to End of Treatment — 0.4; 5.0 mmHg
Morbid Obesity
Primary: Feasibility and Ease of Implantation — 71.8; 81.8; 88.2 percentage of subjects
Facial Rhytides · Glabellar Frown Lines
Primary: Percentage of Participants Achieving a Score of None or Mild by Investigator-Assessed Facial Wrinkle Scale With Photonumeric Guide (FWS) in Forehead Lines at Maximum…
Insomnia
Primary: Incidence of Adverse Events — 81.5; 79.5; 82.1; 87.0 Percentage of Participants
Retinal Vein Occlusion
Primary: Percentage of Participants Who Gained at Least 15 Letters in BCVA as Measured by ETDRS Letter Score Compared With Baseline at Week 24 With Discontinued Participants…
Refractory Partial Seizures
Primary: Percent Change in the 28-day Seizure Frequency From Baseline to the End of the Double-blind Phase (Titration and Maintenance Phases) — -10.69; -13.63; -23.33; -30.80…
Refractory Partial Seizures
Primary: Percent Change in the 28-day Seizure Frequency From Baseline to the End of the Double-blind Phase (Titration and Maintenance Phases) — -9.72; -30.52; -17.57 Percent Change
Chronic Obstructive Pulmonary Disease (COPD)
Primary: Change From Baseline in Mean 24 Hour Heart Rate at Day 14 — -0.113; 0.787; -0.230; 0.240 beats per minute
Vaccine Response Impaired
Primary: Antibody Titer Responses to Hepatitis B Virus Surface Antigen (HBV sAg) Vaccine, Measured and Predicted Based on Pre-vaccination Biomarkers in Healthy, Elderly…
Prevention
Primary: Time From Randomization to Occurrence of Gastric and/or Duodenal Ulcers up to Data Cut-off Date for Interim Analysis. — 1; 16; 1; 4 Participants — p=<0.001
Epilepsy
Primary: Percentage of Responders During the Maintenance Phase — 44.4; 34.2; 55.6; 65.8 Percentage of Participants
Intubation; Difficult
Primary: Endoscopy Scores — 3; 2 units on a scale